Etomoxir

ArtNr	HY-50202-10mM
Hersteller	MedChem Express
CAS-Nr.	124083-20-1
Menge	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 50 mg 5 mg
Kategorie	Oncology Neuroscience Targets for Rodent Neurosciences Cardiovascular Research Myocardial Infarction Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Bladder Cancer Breast Cancer
Typ	Inhibitors
Specific against	other
Purity	99.92
Citations	[1]Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27(7):621-36.\|[2]Xu FY, et al. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells. J Lipid Res. 2003 Feb;44(2):415-23.\|[3]Li J, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep. 2015 Jul 31;5:12724.\|[4]Luiken JJ, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J. 2009 Apr 15;419(2):447-55.\|[5]O'Connor RS, et al. The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. Sci Rep. 2018 Apr 19;8(1):6289. Acta Biomater. 2022 Jul 30;S1742-7061(22)00453-6.\|Acta Pharm Sin B. 2024 Nov 7.\|Adv Sci (Weinh). 2024 Nov 26:e2411559.\|Aging Cell. 2024 Apr 30:e14184.\|Autophagy. 2024 Aug 15.\|Biochem Biophys Res Commun. 2017 Feb 5;483(2):860-866.\|Biochem Biophys Res Commun. 8 October 2021.\|Biochim Biophys Acta Mol Basis Dis. 2024 Jun 25:167314.\|bioRxiv. 2021 Mar 8.\|bioRxiv. 2023 Apr 17.\|bioRxiv. 2023 Nov 17.\|Brain. 2024 Aug 28:awae270.\|Cancer Cell Int. 2023 May 9;23(1):87.\|Cancer Res. 2023 Jun 5;CAN-23-1006.\|Cell Biol Int. 2024 Jun 23.\|Cell Death Dis. 2023 Feb 15;14(2):125.\|Cell Death Dis. 2023 Oct 6;14(10):653.\|Cell Death Discov. 2024 May 1;10(1):207.\|Cell Metab. 2023 Nov 16:S1550-4131(23)00386-8.\|Cell Metab. 2024 May 7;36(5):969-983.e10.\|Cell Physiol Biochem. 2018;48(6):2318-2336. \|Cell Prolif. 2021 Sep 25;e13134.\|Cell Rep Med. 2024 May 29:101592.\|Cell Rep. 2021 Sep 7;36(10):109659.\|Cell Rep. 2024 Feb 27;43(2):113739.\|Cell Signal. 2025 Jan 26:111627.\|Clin Mol Hepatol. 2024 May 10.\|Clin Transl Med. 2022 Sep;12(9):e1061.\|Clin Transl Oncol. 2024 Nov 29.\|Commun Biol. 2022 Dec 7;5(1):1340.\|Engineering. 2024 Sep 6.\|Eur J Med Res. 2025 Jan 17;30(1):35.\|FASEB J. 2025 Mar 15;39(5):e70439.\|Fish Shellfish Immunol. 2024 Aug 12:109829.\|Food Chem Toxicol. 2022 Oct 5;113450.\|Free Radic Biol Med. 2019 Sep;141:372-382.\|Free Radic Biol Med. 2022 Aug 8;190:94-104.\|Front Biosci (Landmark Ed). 2024 Feb 6;29(2):66.\|Front Immunol. 2022 Mar 10;13:771732.\|Front Oncol. 2021 Apr 22;11:665763.\|Front Oncol. 2021 Apr 6.\|Front Pharmacol. 2022 May 16;13:848957.\|Hepatology. 2022 Jan 14.\|Infect Genet Evol. 2020 Nov;85:104552.\|Int J Biol Sci. 2021 Oct 11;17(15):4207-4222.\|Int J Biol Sci. 2022 Mar 14;18(6):2484-2496.\|Int J Biol Sci. 2025 Jan 1;21(2):725-744.\|J Agric Food Chem. 2024 May 29.\|J Biol Chem. 2024 Jul 11:107549.\|J Biomed Mater Res A. 2022 Aug;110(8):1448-1459.\|J Cell Biol. 2022 Dec 5;221(12):e202207022.\|J Cell Sci. 2022 Jul 1;jcs.259090.\|J Invest Dermatol. 2023 Mar 30;S0022-202X(23)01952-8.\|J Orthop Surg Res. 2023 May 26;18(1):386.\|Mol Cell. 2024 Jun 21:S1097-2765(24)00477-5.\|Mol Metab. 2024 May 4:101953.\|Nat Commun. 2021 Jun 16;12(1):3660.\|Nat Commun. 2022 Jun 17;13(1):3486.\|Nat Commun. 2024 Aug 3;15(1):6587.\|Nat Commun. 2024 May 7;15(1):3805.\|Nat Commun. 2025 Feb 1;16(1):1241.\|Nat Commun. 2025 Jan 2;16(1):212.\|Nat Genet. Mar 11.\|Nat Metab. 2022 Oct;4(10):1287-1305.\|Neoplasia. 2025 Feb 3:61:101125.\|Oncol Rep. 2023 Jul;50(1):141.\|Oncol Rep. 2023 May 29.\|Oncotarget. 2016 Oct 11;7(41):67071-67086.\|Pharmacol Res. 2021 Jul 31;105796.\|Proc Natl Acad Sci U S A. 2021 Nov 16;118(46):e2105950118.\|Redox Biol. 2018 Oct;19:412-428. \|Redox Biol. 2021 Jul 26;46:102082.\|Research Square Preprint. 2020 Sep.\|Research Square Preprint. 2022 Feb.\|Rheumatology (Oxford). 2024 Jun 5:keae320.\|Sci Adv. 2023 Apr 14;9(15):eadf8522.\|Sci Immunol. 2023 Sep 29;8(87):eabq2424.\|Sci Rep. 2024 Jan 18;14(1):1600.\|Science Partner Journals. 2023 Feb 14.\|SSRN. 6 Dec 2022.\|Stem Cell Res Ther. 2024 Sep 27;15(1):328.\|Theranostics. 2020 May 16;10(14):6483-6499. \|Universidade de São Paulo. Ribeirão Preto, 2021.\|Vet Microbiol. 2023 Nov 30:288:109932.\|Am J Physiol Cell Physiol. 2025 Jan 27.\|Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e01659-17. \|Cancer Lett. 2024 Jun 18:217068.\|Cell Death Dis. 2022 Mar 11;13(3):229.\|Cell Metab. 2022 Nov 1;34(11):1843-1859.e11.\|Cell Rep. 2019 Apr 2;27(1):226-237.e4.\|J Invest Dermatol. 2023 Mar 30;S0022-202X(23)01952-8.\|Life Sci. 2024 Aug 1:350:122763.\|Lipids Health Dis. 2024 Feb 3;23(1):37.\|Mol Cell. 2020 Oct 1;80(1):43-58.e7.\|Mol Cell. 2022 Jun 15;S1097-2765(22)00539-1.\|Redox Biol. 2018 Jul;17:180-191.\|Research Square Preprint. 2023 Aug 1.
Smiles	O=C(OCC)[C@@]1(OC1)CCCCCCOC2=CC=C(C=C2)Cl
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	(R)-(+)-Etomoxir
Versandbedingung	Gekühlt
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Metabolism-sugar/lipid metabolism
Manufacturer - Targets	Apoptosis
Shipping Temperature	Blue Ice
Storage Conditions	-20°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	326.82
Product Description	Etomoxir ((R)-(+)-Etomoxir) is an irreversible inhibitor of carnitine palmitoyltransferase 1a (CPT-1a), inhibits fatty acid oxidation (FAO) through CPT-1a and inhibits palmitate β-oxidation in human, rat and guinea pig.
Manufacturer - Research Area	Cancer; Metabolic Disease
Solubility	DMSO: 100 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Apoptosis
Clinical information	No Development Reported

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-50202-10mM-safety-datasheet.pdf